MyAirvo 3 (High Flow Nasal Therapy; HFNT) for COPD Patients in the Home

To be eligible to participate in this study, an individual must meet all the following criteria:

1. Provision of signed and dated informed consent form

2. Stated willingness to comply with all study procedures and availability for theduration of the study

3. Male or female, aged 30 years or greater

4. FEV1/FVC of < 70% and an FEV1 of < 80% (GOLD stages II - IV, Grade E)

• Spirometry performed during the screening visit will be used to confirm GOLDstage. A prior spirometric test within the past 6 months can be substituted ifavailable.

5. MRC ≥ 2 or CAT ≥ 10

6. Former smokers or current smokers and never-smokers are eligible for study inclusion

• Current smokers must refrain from smoking when using supplemental oxygen or themyAirvo-3 device

7. History of a severe COPD exacerbation requiring hospitalization in the previous sixweeks

8. COPD in a stable state after hospitalization defined as:

• Clinically stable condition and have had no parenteral therapy for 24 hours.

• Inhaled bronchodilators are required less than four-hourly.

• Oxygen delivery has ceased for 24 hours (unless home oxygen is indicated).

• If previously able, the patient is ambulating safely and independently, andperforming activities of daily living.

• The patient can eat and sleep without significant episodes of dyspnea.

• The patient or caregiver understands and can administer medications.

• Follow-up and home care arrangements (e.g., home oxygen, homecare, Meals onWheels, community nurse, allied health, GP, specialist) have been completed.

9. Willing to adhere to the daily use of the myAirvo 3 regimen for at least 8 hourseach day preferably at night following being shown and using the device

10. Willing to record daily symptoms and pulse oximetry and heart rate on daily basis

11. For females of reproductive potential: use of highly effective contraception for atleast 1 month prior to screening and agreement to use such a method during studyparticipation Highly effective contraception is defined as:

• A tubal ligation:

• An approved hormonal contraceptive such as oral contraceptives, emergencycontraception used as directed, patches, implants, injections, rings orintrauterine devices

12. Able to read and communicate in English

13. Have a home environment suitable for myAirvo 3 use.

14. Agreement to adhere to Lifestyle Considerations (see section 5.3) throughout studyduration - refraining from smoking while receiving supplemental oxygen or themyAirvo-3 device

Exclusion Criteria:

An individual who meets any of the following criteria will be excluded from participation in this study:

1. Current self-reported chronic use of positive airway pressure (PAP) therapy;continuous positive airway pressure (CPAP), or non-invasive positive pressureventilation (NPPV)

2. A STOPBang Questionnaire score > 5*

3. Pregnancy or lactation

4. Treatment with another investigational drug or other intervention within theprevious 30 days

5. Life expectancy less than 12 months due to COPD or other comorbid condition.

6. Recent upper airway surgery (within the previous month)

7. Recent head or neck trauma (within the previous month)

8. Inability to tolerate nasal prongs

9. Requirement of oxygen greater than 15 L/min

• subjects with a STOPBang questionnaire score of > 5 may be eligible if a recentsleep study (within the previous 3 months) shows the absence of obstructivesleep apnea or the subject has, or is at risk of OSA, but refuses to use an OSAdevice and all other eligibility criteria are met.